Prestige Consumer Healthcare (NYSE:PBH) Sets New 52-Week Low - Here's Why

Key Points

• Prestige Consumer Healthcare's stock reached a new 52-week low of $61.78 before closing at $62.76 amidst a trading volume of 37,278 shares.
• Analyst ratings show mixed sentiment, with Sidoti upgrading the stock to a "buy" with a price target of $80, while Zacks downgraded it to "strong sell" and the average consensus price target is $94.80.
• The company's latest earnings report revealed a missed EPS estimate of $0.95 compared to the expected $1.01 and a revenue of $249.53 million, which is down 6.6% year-over-year.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The company traded as low as $61.78 and last traded at $62.76, with a volume of 37278 shares changing hands. The stock had previously closed at $62.97.

Analyst Ratings Changes

A number of brokerages have commented on PBH. Sidoti raised Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Wednesday, September 24th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Zacks Research lowered Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday, September 4th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $94.80.

Prestige Consumer Healthcare Stock Performance

The company has a 50-day moving average of $67.83 and a 200 day moving average of $77.60. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $3.09 billion, a PE ratio of 14.73, a PEG ratio of 1.99 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. During the same quarter in the previous year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare's quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the company. UMB Bank n.a. lifted its stake in shares of Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company's stock valued at $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock valued at $26,000 after acquiring an additional 250 shares during the last quarter. Maseco LLP bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $27,000. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare in the 1st quarter valued at about $38,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.